XML 24 R12.htm IDEA: XBRL DOCUMENT v3.25.3
SUPPLEMENTAL FINANCIAL INFORMATION
 9 Months Ended
Sep. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SUPPLEMENTAL FINANCIAL INFORMATION SUPPLEMENTAL FINANCIAL INFORMATION
Allowance for Doubtful Accounts
The following table is a summary of the changes in our allowance for doubtful accounts for the three and nine months ended September 30, 2025 and 2024.
Three Months Ended September 30,Nine Months Ended September 30,
(in millions)2025202420252024
Balance at beginning of period$71 $67 $71 $62 
Charged to costs and expenses(3)4 (3)4 
Write-offs— (3)(3)(6)
Currency translation adjustments1 (3)4 5 
Balance at end of period$69 $65 $69 $65 
Inventories
(in millions)September 30,
2025		December 31,
2024
Raw materials$573 $510 
Work in process311 266 
Finished goods1,576 1,270 
Inventories$2,460 $2,046 
Property, Plant and Equipment, Net
(in millions)September 30,
2025		December 31,
2024
Property, plant and equipment, at cost$7,750 $7,648 
Accumulated depreciation(4,938)(4,778)
Property, plant and equipment, net$2,812 $2,870 
Other Current Assets and Liabilities
In connection with the sale of our Kidney Care business and pursuant to the EPA, the Kidney Care assets and liabilities in certain countries are to be transferred at a later date for operational, regulatory or other reasons. Accordingly, the related assets, primarily consisting of accounts receivable, of $32 million and liabilities, consisting of accounts payable, of $10 million of these deferred markets and are presented within prepaid and other current assets and accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet as of September 30, 2025.
In the first quarter of 2025, we signed a purchase agreement with a buyer to sell our manufacturing facility in Opelika, Alabama for $25 million, subject to the satisfaction of various closing conditions. The related assets are classified as held-for-sale and are presented within prepaid and other current assets in the accompanying condensed consolidated balance sheet as of September 30, 2025. The net book value of the assets as of September 30, 2025 approximates the transaction price net of estimated selling costs.
Interest Expense, Net
Three Months Ended September 30,Nine Months Ended September 30,
(in millions)2025202420252024
Interest expense, net of capitalized interest$68 $101 $221 $308 
Interest income(10)(14)(41)(57)
Interest expense, net$58 $87 $180 $251 
Other (Income) Expense, Net
Three Months Ended September 30,Nine Months Ended September 30,
(in millions)2025202420252024
Foreign exchange losses, net$3 $7 $15 21 
Pension and other postretirement benefit plans(11)(9)(33)(34)
Change in fair value of marketable equity securities3 — 2 (3)
Equity method investment impairment— — 9 — 
Other, net(2)1 (3)(18)
Other (income) expense, net$(7)$(1)$(10)$(34)
Non-Cash Operating and Investing Activities
Right-of-use operating lease assets obtained in exchange for lease obligations for the nine months ended September 30, 2025 and 2024 were $14 million and $54 million, respectively.
Purchases of property, plant and equipment included in accounts payable as of September 30, 2025 and 2024 were $45 million and $34 million, respectively.